NLRC5 silencing ameliorates cardiac fibrosis by inhibiting the TGF‑β1/Smad3 signaling pathway

Zhou,Hongtao; Yu,Xuefang; Zhou,Guiming

doi:10.3892/mmr.2017.6990

NLRC5 silencing ameliorates cardiac fibrosis by inhibiting the TGF‑β1/Smad3 signaling pathway

Authors:
- Hongtao Zhou
- Xuefang Yu
- Guiming Zhou
View Affiliations

Affiliations: Department of Ultrasound Room, Tianjin Medical University Metabolic Diseases Hospital, Tianjin 300070, P.R. China, Department of Cardiology, Tianjin Medical University General Hospital, Tianjin 300054, P.R. China, Department of Ultrasound Room, Tianjin Medical University General Hospital, Tianjin 300054, P.R. China
Published online on: July 14, 2017 https://doi.org/10.3892/mmr.2017.6990
Pages: 3551-3556

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The proliferation of cardiac fibroblasts (CFs) and excessive deposition of extracellular matrix are the predominant pathological characteristics of cardiac fibrosis. As the largest member of the nucleotide‑binding domain and leucine‑rich repeat (NLR) family, NLRC5 has been shown to be pivotal in the development of hepatic fibrosis. However, whether NLRC5 is involved in the pathogenesis of cardiac fibrosis remains to be elucidated. The present study aimed to investigate the role of NLRC5 and its mechanisms in regulating cardiac fibrosis. CFs were stimulated with transforming growth factor (TGF)‑β1 for various times and the mRNA and protein expression of NLRC5 was assessed using reverse transcription‑quantitative polymerase chain reaction and western blot analysis, respectively. In addition, CFs were transfected with small interfering (si)RNA targeting NLRC5 or scramble siRNA for 24 h and then stimulated with TGF‑β1 for 24 h. Subsequently, cell proliferation was measured using an MTT assay, whereas cell migration was evaluated using a Transwell migration assay. The protein expression levels of α‑smooth muscle actin, collagen I, connective tissue growth factor, phosphorylated‑Smad3 and Smad3 were measured using western blot analysis. The results demonstrated that NLRC5 was upregulated in TGF‑β1‑induced CFs. The knockdown of NLRC5 significantly inhibited cell proliferation and migration, and suppressed myofibroblast differentiation and the expression of pro‑fibrotic molecules in TGF‑β1‑treated CFs. Furthermore, the knockdown of NLRC5 attenuated TGF‑β1‑induced phosphorylation of small mothers against decapentaplegic (Smad)3 in the CFs. The results of the present study indicated that NLRC5 acted as a key regulator of pathological cardiac fibrosis, and NLRC5 silencing ameliorated cardiac fibrosis by inhibiting the TGF‑β1/Smad3 signaling pathway. These results suggested that NLRC5 may be a novel target for attenuating cardiac fibrosis.

View Figures

View References

1	Krenning G, Zeisberg EM and Kalluri R: The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol. 225:631–637. 2010. View Article : Google Scholar : PubMed/NCBI
2	Burlew BS and Weber KT: Cardiac fibrosis as a cause of diastolic dysfunction. Herz. 27:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
3	Leask A: Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res. 106:1675–1680. 2010. View Article : Google Scholar : PubMed/NCBI
4	Spinale FG, Coker ML, Bond BR and Zellner JL: Myocardial matrix degradation and metalloproteinase activation in the failing heart: A potential therapeutic target. Cardiovasc Res. 46:225–238. 2000. View Article : Google Scholar : PubMed/NCBI
5	Brilla CG, Funck RC and Rupp H: Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 102:1388–1393. 2000. View Article : Google Scholar : PubMed/NCBI
6	Lijnen PJ, Petrov VV and Fagard RH: Induction of cardiac fibrosis by transforming growth factor-beta(1). Mol Genet Metab. 71:418–435. 2000. View Article : Google Scholar : PubMed/NCBI
7	Davis BK, Roberts RA, Huang MT, Willingham SB, Conti BJ, Brickey WJ, Barker BR, Kwan M, Taxman DJ, Accavitti-Loper MA, et al: Cutting edge: NLRC5-dependent activation of the inflammasome. J Immunol 186. 186:1333–1337. 2011. View Article : Google Scholar
8	Kuenzel S, Till A, Winkler M, Häsler R, Lipinski S, Jung S, Grötzinger J, Fickenscher H, Schreiber S and Rosenstiel P: The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J Immunol. 184:1990–2000. 2010. View Article : Google Scholar : PubMed/NCBI
9	Meissner TB, Li A, Biswas A, Lee KH, Liu YJ, Bayir E, Iliopoulos D, van den Elsen PJ and Kobayashi KS: NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci USA. 107:13794–13799. 2010. View Article : Google Scholar : PubMed/NCBI
10	Staehli F, Ludigs K, Heinz LX, Seguín-Estévez Q, Ferrero I, Braun M, Schroder K, Rebsamen M, Tardivel A, Mattmann C, et al: NLRC5 deficiency selectively impairs MHC class I-dependent lymphocyte killing by cytotoxic T cells. J Immunol. 188:3820–3828. 2012. View Article : Google Scholar : PubMed/NCBI
11	Xu T, Ni MM, Xing-Li, Li XF, Meng XM, Huang C and Li J: NLRC5 regulates TGF-β1-induced proliferation and activation of hepatic stellate cells during hepatic fibrosis. Int J Biochem Cell Biol. 70:92–104. 2016. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Zhang Y, Huang XR, Wei LH, Chung AC, Yu CM and Lan HY: miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-β/Smad3 signaling. Mol Ther. 22:974–985. 2014. View Article : Google Scholar : PubMed/NCBI
14	Porter KE and Turner NA: Cardiac fibroblasts: At the heart of myocardial remodeling. Pharmacol Ther. 123:255–278. 2009. View Article : Google Scholar : PubMed/NCBI
15	van Nieuwenhoven FA and Turner NA: The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vasc Pharmacol. 58:182–188. 2013. View Article : Google Scholar
16	Lijnen P, Petrov V and Fagard R: Transforming growth factor-beta 1-mediated collagen gel contraction by cardiac fibroblasts. J Renin Angiotensin Aldosterone Syst. 4:113–118. 2003. View Article : Google Scholar : PubMed/NCBI
17	Carver W, Nagpal ML, Nachtigal M, Borg TK and Terracio L: Collagen expression in mechanically stimulated cardiac fibroblasts. Circ Res. 69:116–122. 1991. View Article : Google Scholar : PubMed/NCBI
18	Chen MM, Lam A, Abraham JA, Schreiner GF and Joly AH: CTGF expression is induced by TGF- beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol. 32:1805–1819. 2000. View Article : Google Scholar : PubMed/NCBI
19	Bujak M and Frangogiannis NG: The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res. 74:184–195. 2007. View Article : Google Scholar : PubMed/NCBI
20	Seeland U, Haeuseler C, Hinrichs R, Rosenkranz S, Pfitzner T, Scharffetter-Kochanek K and Böhm M: Myocardial fibrosis in transforming growth factor-beta(1) (TGF-beta(1)) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest. 32:295–303. 2002. View Article : Google Scholar : PubMed/NCBI
21	Zhao XY, Zhao LY, Zheng QS, Su JL, Guan H, Shang FJ, Niu XL, He YP and Lu XL: Chymase induces profibrotic response via transforming growth factor-beta 1/Smad activation in rat cardiac fibroblasts. Mol Cell Biochem. 310:159–166. 2008. View Article : Google Scholar : PubMed/NCBI
22	Araújo-Jorge TC, Waghabi MC, Hasslocher-Moreno AM, Xavier SS, Higuchi Mde L, Keramidas M, Bailly S and Feige JJ: Implication of transforming growth factor-beta1 in Chagas disease myocardiopathy. J Infect Dis. 186:1823–1828. 2002. View Article : Google Scholar : PubMed/NCBI
23	Shyu KG, Wang BW, Chen WJ, Kuan P and Hung CR: Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-beta1 in cultured cardiac fibroblasts. Eur J Heart Fail. 12:219–226. 2010. View Article : Google Scholar : PubMed/NCBI
24	Sassoli C, Chellini F, Pini A, Tani A, Nistri S, Nosi D, Zecchi-Orlandini S, Bani D and Formigli L: Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling. PLoS One. 8:e638962013. View Article : Google Scholar : PubMed/NCBI
25	Leask A: TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res. 74:207–212. 2007. View Article : Google Scholar : PubMed/NCBI
26	Bujak M, Ren G, Kweon HJ, Dobaczewski M, Reddy A, Taffet G, Wang X-F and Frangogiannis NG: Essential role of Smad3 in infarct healing and in the pathogenesis of cardiac remodeling. Circulation. 116:2127–2138. 2007. View Article : Google Scholar : PubMed/NCBI
27	Dobaczewski M, Bujak M, Li N, Gonzalez-Quesada C, Mendoza LH, Wang XF and Frangogiannis NG: Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res. 107:418–428. 2010. View Article : Google Scholar : PubMed/NCBI